Abnormal signal pathways and tumor heterogeneity in osteosarcoma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Osteosarcoma (OS) is a prevalent and aggressive bone cancer in adolescents.
• Current chemotherapy options for OS have seen limited advancement over decades.
• Urgent need exists for novel insights into OS pathogenesis and improved therapeutic strategies.

Purpose of the Study:

• To investigate the molecular mechanisms underlying osteosarcoma development.
• To identify potential novel driver mutations and aberrant signaling pathways in OS.
• To explore tumor heterogeneity and its implications for treatment.

Main Methods:

• Integrated analysis of single-cell transcriptomes, bulk RNA-seq, and microarray data from GEO datasets.
• Application of Weighted Gene Co-expression Network Analysis (WGCNA), Gene set enrichment analysis (GSEA), and Gene set variation analysis (GSVA).
• Utilized Simple ClinVar and Enrichr web servers for data interpretation.

Main Results:

• OS originates from imperfect osteogenesis, involving deficient TGFβ and P53 signaling pathways.
• Identified a potential novel driver mutation in Interferon Induced Transmembrane Protein 5 (IFITM5) as a pathogenic factor.
• Revealed significant oncocyte heterogeneity in OS, with distinct immunogenic and adipocyte-like subtypes impacting treatment.
• Etoposide shows promise by targeting specific OS subtypes and correcting aberrant pathways.

Conclusions:

• Aberrant signaling pathways are critical in osteosarcoma progression.
• Understanding OS heterogeneity and molecular mechanisms aids in treatment selection.
• Findings provide a basis for improved OS assessment and personalized therapeutic strategies.